Rheumatoid arthritis
Conditions
Interventions
Control group:Standard doses
Experimental group:Gradual dose reduction
Sponsors
Gansu Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years, no gender limitation; 2. RA patients diagnosed according to the RA classification standard issued by the American College of Rheumatology (ACR) in 1987 and the RA classification standard issued by ACR/EULAR in 2010; 3. Patients treated RA with maintained stable doses of adamu monoantigen, inasip, lytoxides, inflixi monoantigens, etc. during the past 6 months; 4. RA patients who have maintained clinical remission in the past 6 months; 5. Patients with no progress of structural damage to hand, foot and joint X-rays in the past 1 year; 6. Participants participated knowingly and voluntarily and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Current oral glucoticoid therapists; 2. RA patients who have been given corticosteroids or short-term oral glucoticoids in the joints or intestines in the past 6 months; 3. Patients who are addicted to alcohol or drug; 4. Patients with psychological/mental disorders that may invalidate informed consent; 5. Patients who are pregnant, nursing or have a pregnancy plan; 6. Patients with contraindications of bDMARDs maintenance treatment; 7. Patients with malignant tumors or a history of malignant tumors; 8. Patients with other autoimmune diseases; 9. Patients participated in other clinical studies during this trial or within 30 days; 10. Other situations in which the researchers did not consider it appropriate to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| persistent flare; | — |
Secondary
| Measure | Time frame |
|---|---|
| cumulative flare;disease activity during follow-up;physical function;quality of life;imaging performance and imaging progress;the proportion of clinical remission and LDA maintained at the end of the follow-up;the proportion of patients in the observation group who successfully reduced the drug;the proportion of patients in observation group who successfully discontinued the drug;occurrence of adverse events; | — |
Countries
China
Contacts
Public ContactLei Shangwen
Gansu Provincial People's Hospital
Outcome results
None listed